Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When will tenofovir alafenide come off patent in canada?
When did risperdal constas patent expire published article?
When will generic fiasap insulin be available?
How does iron rich food intake impact lipitor's efficacy?
Mobic injection patent oehringer ingelheim france?

Vocabria nda approval?

See the DrugPatentWatch profile for Vocabria

What does “Vocabria NDA approval” mean?

“Vocabria” is the brand name for cabotegravir. An “NDA approval” refers to the U.S. Food and Drug Administration (FDA) approval of a New Drug Application submitted by the manufacturer.

What is Vocabria’s NDA status in the U.S.?

I can’t confirm Vocabria’s specific NDA approval status or the exact approval date from the information provided here. If you share the manufacturer (or a link to the FDA page you’re looking at), I can help interpret what the NDA approval means (and what labeling/indications it covers).

When was Vocabria approved, and for what use?

Vocabria is used as part of an HIV treatment regimen, including as lead-in or oral therapy prior to longer-acting injectable cabotegravir/rilpivirine in appropriate patients. Exact regulatory details depend on the specific FDA approval action reflected on the NDA record.

Where to check the official FDA record?

For the most accurate “NDA approval” confirmation, look up the drug in:
- FDA’s Drugs@FDA database (for NDA number, approval date, and labeling)
- The FDA approval letter or labeling text associated with the NDA

If you paste the NDA number you’re seeing (or the URL), I can tell you what it indicates and help summarize the key parts of the approval.

If you meant another country (not FDA NDA)

Some regions use different approval frameworks (for example, EMA marketing authorization instead of FDA NDA). “NDA approval” typically points to the U.S., but the term can be used loosely. Tell me which country/regulator you mean.

Tell me one detail and I’ll narrow it down

Which NDA record are you referring to—do you have the NDA number, the manufacturer name, or the link to the page?



Other Questions About Vocabria :

vocabria cost vocabria vocabria generic vocabria tablet vocabria price Can Vocabria be used with Rekambys?

AI-Drug Label Prescribing Information Alignment Report

72
72%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Some claims are supported by the provided label excerpts (brand/active ingredient; use in HIV treatment; lead-in prior to long-acting injectable). However, the explanation of “NDA approval” is not a claim supported by prescribing information and is evaluated as unsupported, reducing overall alignment.

Category Scores

Indication
90
Excellent
Dosage
85
Good
SpecificPopulations
80
Good
Administration
75
Good

Accurate Statements

Vocabria is the brand name for cabotegravir.
Provided label excerpt identifies VOCABRIA as cabotegravir (Drug: VOCABRIA; Active ingredient: cabotegravir; and label text repeatedly refers to VOCABRIA/cabotegravir).
Vocabria is used as part of an HIV treatment regimen.
Label 1.1: VOCABRIA is indicated in combination with EDURANT (rilpivirine) tablets for short-term treatment of HIV-1 infection.
Vocabria is used as lead-in or oral therapy prior to longer-acting injectable cabotegravir/rilpivirine in appropriate patients.
Label 1.1: oral lead-in to assess tolerability of cabotegravir prior to administration of cabotegravir extended-release injectable suspension (CABENUVA); and oral therapy for patients who will miss planned injection dosing with CABENUVA.

Unsupported Statements

In the U.S., “NDA approval” refers to FDA approval of a New Drug Application submitted by the manufacturer.
Not a claim addressed in the provided prescribing information excerpts; the label excerpts do not define or explain the term “NDA approval.”

Contradictions

Important Omissions

For the lead-in/“appropriate patients” statement, the label specifies detailed eligibility criteria (e.g., virologically suppressed on a stable regimen with no history of treatment failure and no known/suspected resistance to cabotegravir or rilpivirine; and for PrEP also negative HIV-1 test requirements).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated unsupported content is a regulatory-definition statement rather than drug-safety/dosing/contraindication guidance. The supported clinical use statements are broadly accurate but lack some label-specified patient-selection details.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Contains one unsupported non-label claim about the meaning of “NDA approval,” and the “appropriate patients” phrasing omits label-specified eligibility details.

Suggested Improvement
Remove or rephrase the “NDA approval” definition. For clinical use, include the label’s specific eligibility requirements (as applicable) rather than relying on general “appropriate patients” wording.

Drug Brand Mention Assessment

Branding Score
22
Visibility
34
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

brand name for cabotegravir

Core Claims
  • “Vocabria” is the brand name for cabotegravir.
  • “NDA approval” refers to FDA approval of a New Drug Application submitted by the manufacturer.
  • I can’t confirm Vocabria’s specific NDA approval status or the exact approval date from the information provided here.
  • Vocabria is used as part of an HIV treatment regimen, including as lead-in or oral therapy prior to longer-acting injectable cabotegravir/rilpivirine in appropriate patients.
Differentiators
Pricing Perception: Not Mentioned